Figure 1 (Spevigo 01)
This is a description of a clinical trial comparing a placebo treatment to a medication called "SPEVIGO 600mg LD/300 mg" administered every 4 weeks. The chart shows the number of subjects at risk in both the placebo and SPEVIGO groups over a period of 48 weeks. This information is useful for evaluating the efficacy and safety of the medication compared to a placebo in the study participants.*